{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:20:16Z","timestamp":1792063216108,"version":"4.4.0"},"reference-count":201,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers worldwide. More than half of patients with HNSCC eventually experience disease recurrence and\/or metastasis, which can threaten their long-term survival. HNSCCs located in the oral cavity and larynx are usually associated with tobacco and\/or alcohol use, whereas human papillomavirus (HPV) infection, particularly HPV16 infection, is increasingly recognized as a cause of oropharyngeal HNSCC. Despite clinical, histologic, and molecular differences between HPV-positive and HPV-negative HNSCCs, current treatment approaches are the same. For recurrent disease, these strategies include chemotherapy, immunotherapy with PD-1-inhibitors, or a monoclonal antibody, cetuximab, that targets epidermal growth factor; these therapies can be administered either as single agents or in combination. However, these treatment strategies carry a high risk of toxic side effects; therefore, more effective and less toxic treatments are needed. The landscape of HNSCC therapy is changing significantly; numerous clinical trials are underway to test novel therapeutic options like adaptive cellular therapy, antibody-drug conjugates, new targeted therapy agents, novel immunotherapy combinations, and therapeutic vaccines. This review helps in understanding the various developments in HNSCC therapy and sheds light on the path ahead in terms of further research in this field.<\/jats:p>","DOI":"10.3390\/ijms23147889","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T22:57:06Z","timestamp":1658098626000},"page":"7889","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-8538","authenticated-orcid":false,"given":"Soma","family":"Ghosh","sequence":"first","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 432, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-0443","authenticated-orcid":false,"given":"Pooja A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 432, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 432, Houston, TX 77030, USA"},{"name":"Graduate School of Biomedical Sciences, The University of Texas, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cas.14784","article-title":"Personalized cancer vaccination in head and neck cancer","volume":"112","author":"Shibata","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1200\/JCO.2006.07.1829","article-title":"Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: Implications for clinical research in head and neck cancers","volume":"24","author":"Gillison","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mayocp.2015.12.017","article-title":"Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment","volume":"91","author":"Marur","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/CEJ.0000000000000554","article-title":"Epstein-Barr virus molecular epidemiology and variants identification in head and neck squamous cell carcinoma","volume":"29","author":"Keyvani","year":"2020","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_6","first-page":"476","article-title":"Cancers of the lung, head and neck on the rise: Perspectives on the genotoxicity of air pollution","volume":"33","author":"Wong","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7314\/APJCP.2014.15.2.537","article-title":"Head and neck cancer: Global burden and regional trends in India","volume":"15","author":"Mishra","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40348-014-0009-8","article-title":"Fanconi anemia: Young patients at high risk for squamous cell carcinoma","volume":"1","author":"Velleuer","year":"2014","journal-title":"Mol. Cell. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/ijc.28811","article-title":"High-risk HPV types and head and neck cancer","volume":"135","author":"Michaud","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"djv403","DOI":"10.1093\/jnci\/djv403","article-title":"HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients","volume":"108","author":"Castellsague","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517, 576\u2013582.","DOI":"10.1038\/nature14129"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41199-018-0039-3","article-title":"HPV-driven oropharyngeal cancer: Current knowledge of molecular biology and mechanisms of carcinogenesis","volume":"3","author":"Pan","year":"2018","journal-title":"Cancers Head Neck"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: Molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(05)66658-5","article-title":"Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial","volume":"365","author":"Sankaranarayanan","year":"2005","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1758835920949418","DOI":"10.1177\/1758835920949418","article-title":"Head and neck cancer: The role of anti-EGFR agents in the era of immunotherapy","volume":"13","author":"Fasano","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fonc.2017.00072","article-title":"Evidence-Based Treatment Options in Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck","volume":"7","author":"Argiris","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0360-3016(92)90642-U","article-title":"Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034","volume":"23","author":"Laramore","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0360-3016(96)00430-0","article-title":"Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial","volume":"36","author":"Bachaud","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/lio2.487","article-title":"Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI)","volume":"5","author":"Mott","year":"2020","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"834068","DOI":"10.3389\/fonc.2022.834068","article-title":"Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer","volume":"12","author":"McDowell","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0022034514524783","article-title":"Harnessing massively parallel sequencing in personalized head and neck oncology","volume":"93","author":"Jessri","year":"2014","journal-title":"J. Dent. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.oraloncology.2013.12.017","article-title":"Next generation sequencing and its application in deciphering head and neck cancer","volume":"50","author":"Jessri","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","first-page":"1111","article-title":"Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas","volume":"4","author":"Berenson","year":"1989","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hed.23100","article-title":"Lessons learned from next-generation sequencing in head and neck cancer","volume":"35","author":"Loyo","year":"2013","journal-title":"Head Neck"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.241141.118","article-title":"Human papillomavirus and the landscape of secondary genetic alterations in oral cancers","volume":"29","author":"Gillison","year":"2019","journal-title":"Genome Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.oraloncology.2017.08.010","article-title":"Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils","volume":"73","author":"Ilmarinen","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Melhem","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-015-0633-7","article-title":"Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer","volume":"13","author":"Zazo","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(10)70017-6","article-title":"HPV-associated head and neck cancer: A virus-related cancer epidemic","volume":"11","author":"Marur","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.amjoto.2011.02.001","article-title":"Human papillomavirus, smoking, and head and neck cancer","volume":"33","author":"Sinha","year":"2012","journal-title":"Am. J. Otolaryngol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1940-6207.CAPR-17-0140","article-title":"High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral\/Head and Neck Cancer Risk in Smokers","volume":"10","author":"Khariwala","year":"2017","journal-title":"Cancer Prev. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/carcin\/bgn062","article-title":"Gene-environment interaction in tobacco-related cancers","volume":"29","author":"Taioli","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hed.20573","article-title":"Current topics in the epidemiology of oral cavity and oropharyngeal cancers","volume":"29","author":"Gillison","year":"2007","journal-title":"Head Neck"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41416-020-01031-z","article-title":"Alcohol drinking and head and neck cancer risk: The joint effect of intensity and duration","volume":"123","author":"Polesel","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1158\/1055-9965.EPI-19-0038","article-title":"Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States","volume":"28","author":"Mahal","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41199-016-0003-z","article-title":"Genomic insights into head and neck cancer","volume":"1","author":"Beck","year":"2016","journal-title":"Cancers Head Neck"},{"key":"ref_42","first-page":"3579","article-title":"Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer","volume":"53","author":"Grandis","year":"1993","journal-title":"Cancer Res."},{"key":"ref_43","first-page":"507","article-title":"Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC)","volume":"21","author":"Azoury","year":"2016","journal-title":"Discov. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/cncr.23442","article-title":"Overview of the efficacy of cetuximab in recurrent and\/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies","volume":"112","author":"Vermorken","year":"2008","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Ohba, M., and Ohmori, T. (2017). Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112420"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck","volume":"27","author":"Stewart","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdu216","article-title":"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"25","author":"Seiwert","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/annonc\/mdz388","article-title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): An open-label, randomised phase III trial","volume":"30","author":"Guo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/JCO.2020.38.15_suppl.6504","article-title":"Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations","volume":"38","author":"Ho","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113729","DOI":"10.1016\/j.bcp.2019.113729","article-title":"PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer","volume":"172","author":"Marquard","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41199-018-0030-z","article-title":"Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)","volume":"3","author":"Jung","year":"2018","journal-title":"Cancers Head Neck"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e184475","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.molonc.2013.03.004","article-title":"A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins","volume":"7","author":"Keysar","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1038\/ncomms14292","article-title":"Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma","volume":"8","author":"Mizrachi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_65","first-page":"175","article-title":"In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer","volume":"35","author":"Keam","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1158\/0008-5472.CAN-05-0921","article-title":"Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck","volume":"65","author":"Amornphimoltham","year":"2005","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1158\/0008-5472.CAN-09-1077","article-title":"Genetic alterations in the phosphoinositide 3-kinase\/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41416-020-01074-2","article-title":"Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck","volume":"123","author":"Kim","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"v455","DOI":"10.1093\/annonc\/mdz252.012","article-title":"Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial","volume":"30","author":"Fayette","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","article-title":"First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","article-title":"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)","volume":"96","author":"Wicki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-16-1080","article-title":"Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors","volume":"7","author":"Juric","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","article-title":"A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kalpha Isoform Inhibitor, in Patients with Advanced Solid Malignancies","volume":"23","author":"Juric","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-Kinase alpha-Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.oraloncology.2014.12.013","article-title":"A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","volume":"51","author":"Jimeno","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdu574","article-title":"A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","volume":"26","author":"Jimeno","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): A randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Soulieres","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-021-01152-z","article-title":"Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"39","author":"Marret","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e150335","DOI":"10.1172\/JCI150335","article-title":"Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma","volume":"131","author":"Jin","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/0008-5472.CAN-15-1654","article-title":"Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations","volume":"75","author":"Dogruluk","year":"2015","journal-title":"Cancer Res"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/1535-7163.MCT-13-1090","article-title":"A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma","volume":"13","author":"Mazumdar","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shah, P.A., Huang, C., Li, Q., Kazi, S.A., Byers, L.A., Wang, J., Johnson, F.M., and Frederick, M.J. (2020). NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells, 9.","DOI":"10.3390\/cells9122677"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-18-3276","article-title":"PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K\/mTOR Inhibition","volume":"25","author":"Sambandam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nchembio.695","article-title":"A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer","volume":"7","author":"Muellner","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"B109","DOI":"10.1158\/1535-7163.TARG-19-B109","article-title":"Abstract B109: Oral dual PI3K\/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation","volume":"18","author":"Janku","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"TPS6590","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6590","article-title":"Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations","volume":"38","author":"Johnson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1538-7445.AM2018-2977","article-title":"Abstract 2977: PI3K\/mTOR pathway inhibition induces Aurora B mediated cell death inNOTCH1mutant head and neck squamous (HNSCC) cells","volume":"78","author":"Sambandam","year":"2018","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ijrobp.2019.11.117","article-title":"Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma","volume":"106","author":"Sambandam","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Shah, P.A., Fernandez, A.M., Sambandam, V., Zhao, H., Mazumdar, T., Shen, L., Wang, J., and Johnson, F.M. (2022, January 8\u201313). Aurora kinase B expression shields HNSCC from PI3K inhibition-induced apoptosis through downstream mediators AKT and PDK1. Proceedings of the AACR Annual Meeting 2022, New Orleans, LA, USA.","DOI":"10.1158\/1538-7445.AM2022-3251"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3727\/000000006783991962","article-title":"Gene expression profiles of the aurora family kinases","volume":"13","author":"Lin","year":"2006","journal-title":"Gene Expr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1535-7163.MCT-15-0506","article-title":"Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer","volume":"14","author":"Gabrielli","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.oraloncology.2018.09.006","article-title":"Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers","volume":"86","author":"Shaikh","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/1535-7163.MCT-17-0159","article-title":"Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors","volume":"16","author":"Martin","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","first-page":"3240","article-title":"Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing","volume":"11","author":"Tayyar","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Ghosh, S., Mazumdar, T., Xu, W., Powell, R.T., Stephan, C., Shen, L., Pickering, C.R., Wang, J., and Johnson, F.M. (2022, January 8\u201313). Rb deficient HPV+ HNSCC experienced enhanced sensitivity to aurora kinase inhibitors by altering the balance of MAD2 and TRIP13 levels. Proceedings of the AACR Annual Meeting 2022, New Orleans, LA, USA.","DOI":"10.1158\/1538-7445.AM2022-1858"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","article-title":"Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival","volume":"9","author":"Oser","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1038\/s41467-020-18872-0","article-title":"Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics","volume":"11","author":"Lyu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","article-title":"Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)","volume":"43","author":"Freier","year":"2007","journal-title":"Oral Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hed.23312","article-title":"Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models","volume":"36","author":"Wheeler","year":"2014","journal-title":"Head Neck"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40291-016-0204-5","article-title":"FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma","volume":"20","author":"Koole","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/modpathol.2013.58","article-title":"Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck","volume":"26","author":"Goke","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1101\/gr.275911.121","article-title":"Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers","volume":"32","author":"Symer","year":"2022","journal-title":"Genome Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bednova, O., and Leyton, J.V. (2020). Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197268"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00100","article-title":"Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient with Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications","volume":"2","author":"Dumbrava","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","article-title":"Recent developments in epigenetic cancer therapeutics: Clinical advancement and emerging trends","volume":"28","author":"Nepali","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Nakagawa, T., Kurokawa, T., Mima, M., Imamoto, S., Mizokami, H., Kondo, S., Okamoto, Y., Misawa, K., Hanazawa, T., and Kaneda, A. (2021). DNA Methylation and HPV-Associated Head and Neck Cancer. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040801"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3389\/fimmu.2019.01023","article-title":"Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_117","first-page":"136","article-title":"Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein","volume":"12","author":"Heydar","year":"2018","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-9966-31-37","article-title":"Enhancement of radiation response with bevacizumab","volume":"31","author":"Hoang","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.19.00555","article-title":"Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer","volume":"37","author":"Argiris","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"683570","DOI":"10.3389\/fonc.2021.683570","article-title":"Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?","volume":"11","author":"Wahbi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.oraloncology.2013.04.010","article-title":"A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)","volume":"49","author":"Limaye","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.23898","article-title":"Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and\/or metastatic head and neck cancer","volume":"38","author":"Lalami","year":"2016","journal-title":"Head Neck"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/annonc\/mds581","article-title":"Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma","volume":"24","author":"Xue","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/cts.13002","article-title":"Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics\/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer","volume":"15","author":"Even","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: A double-blind, multicentre, randomised, phase 2 study","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_126","unstructured":"Debiopharm (2022, June 16). Novel IAP Inhibitor Shows Significant OS Benefit for High-Risk Head and Neck Cancer. In targetedonc.com. Available online: https:\/\/www.targetedonc.com\/view\/novel-iap-inhibitor-shows-significant-os-benefit-for-high-risk-head-and-neck-cancer."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/1535-7163.MCT-20-0599","article-title":"Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides","volume":"20","author":"Shiah","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/172460080602100307","article-title":"Stat3 expression in oral squamous cell carcinoma: Association with clinicopathological parameters and survival","volume":"21","author":"Shah","year":"2006","journal-title":"Int. J. Biol. Markers"},{"key":"ref_129","first-page":"3351","article-title":"Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma","volume":"62","author":"Masuda","year":"2002","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/1535-7163.MCT-05-0069","article-title":"Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and\/or MEK in head and neck squamous cell carcinomas","volume":"5","author":"Lee","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"26307","DOI":"10.18632\/oncotarget.8368","article-title":"Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma","volume":"7","author":"Bharadwaj","year":"2016","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1172\/JCI3785","article-title":"Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro","volume":"102","author":"Grandis","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1073\/pnas.97.8.4227","article-title":"Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo","volume":"97","author":"Grandis","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI60083","article-title":"STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Pan","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Su, Y.L., Banerjee, S., White, S.V., and Kortylewski, M. (2018). STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061803"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4291\/wjgp.v6.i3.43","article-title":"Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis","volume":"6","author":"Hammerich","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer\u2014Using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/gutjnl-2014-307990","article-title":"Current concepts of immune based treatments for patients with HCC: From basic science to novel treatment approaches","volume":"64","author":"Greten","year":"2015","journal-title":"Gut"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"E2801","DOI":"10.1073\/pnas.1707929115","article-title":"Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition","volume":"115","author":"Giurisato","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/stem.1281","article-title":"Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR\/Stat3\/Sox-2 signaling pathway","volume":"31","author":"Yang","year":"2013","journal-title":"Stem Cells"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/TP.0b013e3181739d25","article-title":"STAT3: An important regulator of multiple cytokine functions","volume":"85","author":"Stepkowski","year":"2008","journal-title":"Transplantation"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","article-title":"Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis","volume":"32","author":"Durant","year":"2010","journal-title":"Immunity"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2014.00276","article-title":"Th17 cells in cancer: The ultimate identity crisis","volume":"5","author":"Bailey","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"viii372","DOI":"10.1093\/annonc\/mdy287","article-title":"1044O A phase Ib\/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent\/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results","volume":"29","author":"Cohen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.ijrobp.2021.12.028","article-title":"Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort","volume":"112","author":"Hong","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fimmu.2020.01721","article-title":"The Evolving Landscape of PD-1\/PD-L1 Pathway in Head and Neck Cancer","volume":"11","author":"Qiao","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-Year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab Alone or With Chemotherapy for Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score","volume":"40","author":"Burtness","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J. Immunother Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2019.37.15_suppl.6000","article-title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"37","author":"Rischin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fonc.2019.00827","article-title":"Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting","volume":"9","author":"Economopoulou","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.tranon.2020.100811","article-title":"Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?","volume":"13","author":"Solinas","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e03224-20","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody","volume":"12","author":"Peng","year":"2021","journal-title":"mBio"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Zhou, J.Z., Jou, J., and Cohen, E. (2021). Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. Cancers, 14.","DOI":"10.3390\/cancers14010033"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fimmu.2018.00830","article-title":"Targeting Head and Neck Cancer by Vaccination","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/annonc\/mdz253.036","article-title":"1210P\u2014Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic (R\/M) HPV-16+ cancers","volume":"30","author":"Tourneau","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e20200389","DOI":"10.1084\/jem.20200389","article-title":"Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients","volume":"217","author":"Bhatt","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e1363139","DOI":"10.1080\/2162402X.2017.1363139","article-title":"Trial Watch: Adoptively transferred cells for anticancer immunotherapy","volume":"6","author":"Fournier","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2018.36.15_suppl.3046","article-title":"A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC)","volume":"36","author":"Papa","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","article-title":"Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6","volume":"21","author":"Draper","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2017.35.15_suppl.3009","article-title":"A phase I\/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers","volume":"35","author":"Hinrichs","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e1498439","DOI":"10.1080\/2162402X.2018.1498439","article-title":"Treatment-naive HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV-counterparts that has implications for immunotherapy","volume":"7","author":"Gameiro","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Le, X., Dang, M., Hegde, V.L., Jiang, B., Slay, R., Xiao, W., Akagi, K., Fresquez, J., Marcelo, K.L., and Luo, Q. (2021). TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas. medRxiv.","DOI":"10.1101\/2021.12.02.21266776"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/JCMA.0000000000000497","article-title":"Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer","volume":"84","author":"Chen","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Saba, N.F., Ekpenyong, A., McCook-Veal, A., Patel, M., Schmitt, N.C., Stokes, W.A., Bates, J.E., Rudra, S., Abousaud, M.I., and Muzaffar, J. (2022, January 3\u20137). A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Proceedings of the ASCO 2022, Chicago, IL, USA.","DOI":"10.1200\/JCO.2022.40.16_suppl.6008"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Caforio, M., de Billy, E., De Angelis, B., Iacovelli, S., Quintarelli, C., Paganelli, V., and Folgiero, V. (2021). PI3K\/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. Cancers, 13.","DOI":"10.3390\/cancers13164040"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e002088","DOI":"10.1136\/jitc-2020-002088","article-title":"Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck","volume":"9","author":"Zandberg","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1535-7163.MCT-14-0888","article-title":"The PI3K\/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1alpha Phosphorylation","volume":"14","author":"Cerniglia","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41467-021-27833-0","article-title":"Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kalpha\/beta\/delta treatment","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3Kdelta inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Chung, C.H., Bonomi, M., Steuer, C.E., Li, J., Bhateja, P., Johnson, M., Masannat, J., Song, F., Hernandez-Prera, J.C., and Wenig, B.M. (2021). Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I\/II Study. Cancers, 13.","DOI":"10.3390\/cancers13051180"},{"key":"ref_195","unstructured":"(2022, April 26). NCCN Guidelines for Head and Neck Cancers, Version 2.2022. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_197","unstructured":"BMS (2022, June 16). Bristol Myers Squibb Provides Update on CheckMate-651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck. Available online: https:\/\/www.ono-pharma.com\/news\/20210719.html."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","article-title":"CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies","volume":"26","author":"Quayle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_199","first-page":"A468","article-title":"438\u2005A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent\/metastatic HPV16+ head and neck cancer","volume":"9","author":"Chung","year":"2021","journal-title":"J. Immunother Cancer"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7889\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:35Z","timestamp":1760140355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":201,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23147889"],"URL":"https:\/\/doi.org\/10.3390\/ijms23147889","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]}}}